Clinical and genetic modifiers of long-term survival in heart failure
S Cresci, RJ Kelly, TP Cappola, A Diwan… - Journal of the American …, 2009 - jacc.org
S Cresci, RJ Kelly, TP Cappola, A Diwan, D Dries, SLR Kardia, GW Dorn
Journal of the American College of Cardiology, 2009•jacc.orgObjectives: This study sought to identify genetic modifiers of β-blocker response and long-
term survival in heart failure (HF). Background: Differences in β-blocker treatment effect
between Caucasians and African Americans with HF have been reported. Methods: This
was a prospective cohort study of 2,460 patients (711 African American, 1,749 Caucasian)
enrolled between 1999 and 2007; 2,039 patients (81.7%) were treated with a β-blocker.
Each was genotyped for β1-adrenergic receptor (ADRB1) Arg389> Gly and G-protein …
term survival in heart failure (HF). Background: Differences in β-blocker treatment effect
between Caucasians and African Americans with HF have been reported. Methods: This
was a prospective cohort study of 2,460 patients (711 African American, 1,749 Caucasian)
enrolled between 1999 and 2007; 2,039 patients (81.7%) were treated with a β-blocker.
Each was genotyped for β1-adrenergic receptor (ADRB1) Arg389> Gly and G-protein …
Objectives
This study sought to identify genetic modifiers of β-blocker response and long-term survival in heart failure (HF).
Background
Differences in β-blocker treatment effect between Caucasians and African Americans with HF have been reported.
Methods
This was a prospective cohort study of 2,460 patients (711 African American, 1,749 Caucasian) enrolled between 1999 and 2007; 2,039 patients (81.7%) were treated with a β-blocker. Each was genotyped for β1-adrenergic receptor (ADRB1) Arg389>Gly and G-protein receptor kinase 5 (GRK5) Gln41>Leu polymorphisms, which are more prevalent among African Americans than Caucasians. The primary end point was survival time from HF onset.
Results
There were 765 deaths during follow-up (median 46 months). β-blocker treatment increased survival in Caucasians (log-rank p = 0.00038) but not African Americans (log-rank p = 0.327). Among patients not taking β-blockers, ADRB1Gly389 was associated with decreased survival in Caucasians (hazard ratio [HR]: 1.98, 95% confidence interval [CI]: 1.1 to 3.7, p = 0.03) whereas GRK5Leu41 was associated with improved survival in African Americans (HR: 0.325, CI: 0.133 to 0.796, p = 0.01). African Americans with ADRB1Gly389Gly GRK5Gln41Gln derived a similar survival benefit from β-blocker therapy (HR: 0.385, 95% CI: 0.182 to 0.813, p = 0.012) as Caucasians with the same genotype (HR: 0.529, 95% CI: 0.326 to 0.858, p = 0.0098).
Conclusions
These data show that differences caused by β-adrenergic receptor signaling pathway gene polymorphisms, rather than race, are the major factors contributing to apparent differences in the β-blocker treatment effect between Caucasians and African Americans; proper evaluation of treatment response should account for genetic variance.
jacc.org